Who
Arvind Kush
Director
Company insider
Files Form 4 as: Director, Inhibikase Therapeutics; Chief Financial Officer, RayzeBio.
In numbers
- Trades disclosed
- 12
- Buys
- 1
- Sells
- 0
- Bought
- $199K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 17 Nov 2023
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —108,176 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,600 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —116,585 at $0.00 | filing |
| 21 Oct 2024filed 23 Oct 2024 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 21 Oct 2024filed 23 Oct 2024 | IKT Inhibikase TherapeuticsBiotechnology | SEC FORM 4 Bought | $199K145,000 at $1.37 | filing |
| 26 Feb 2024filed 27 Feb 2024 | RayzeBiooption or derivative | SEC FORM 4 Code D | —301,745 | filing |
| 26 Feb 2024filed 27 Feb 2024 | RayzeBiooption or derivative | SEC FORM 4 Code D | —149,777 | filing |
| 26 Feb 2024filed 27 Feb 2024 | RayzeBiooption or derivative | SEC FORM 4 Code D | —164,000 | filing |
| 26 Feb 2024filed 27 Feb 2024 | RayzeBio | SEC FORM 4 Code D | $4.9M78,433 at $62.50 | filing |
| 17 Nov 2023filed 17 Nov 2023 | RayzeBiooption or derivative | SEC FORM 4 Code A | —164,000 at $0.00 | filing |
News
Head-To-Head Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus CorMedix (NASDAQ:CRMD)IKT · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Arvind Kush; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.